Xenikos is developing a combination of two toxin-loaded anti-T-cell antibodies.
Xenikos aims to develop a new medicine, based on the action of antibodies that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos strives to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 19, 2022 | Grant | — | 1 |
![]() |
— | Detail |
Sep 8, 2021 | Convertable Note | €40M | 1 | — | — | Detail |
Jun 19, 2012 | Debt Financing | €1.90M | 1 |
|
— | Detail |
Jun 19, 2012 | Series A | €3.60M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Grant |
|
Yes | Debt Financing |
|
— | Convertable Note |
|
— | Series A |